Manuel Enrique's 50-day peptide test: what he got right
Quick answer
This video documents self-administration of at least two growth hormone-related and skin-remodeling peptides, GHK-Cu and CJC-1295, via subcutaneous injection over 50 days without reported physician supervision, baseline bloodwork, or consistent protocol adherence. CJC-1295 is a growth hormone-releasing hormone analogue with documented effects on GH and IGF-1 levels that warrant monitoring, particularly in the context of undisclosed mid-experiment protocol deviations. The absence of final results in the TikTok itself means 410,000 viewers received a record of protocol errors and anecdotal skin observations with no outcome data to evaluate.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @manuelenriqueee actually say?
The creator ran a 50-day self-experiment using three peptides, at minimum GHK-Cu and CJC-1295, to test skin improvement, scar reduction, and physique changes. He tracked baseline strength at 100-lb dumbbells for five reps and photographed his skin. He later admitted he had been co-injecting GHK-Cu and CJC-1295 for 21 days, calling it a mistake because "the effects aren't gonna be as good." He ran out of GHK-Cu on day 24, had delivery delays, and then started doing something unspecified that he "wasn't supposed to do." The full results are only on YouTube, meaning this TikTok at 410K views is a highlight reel of protocol errors, not a documented transformation.
Does the science back this up?
Weakly, and mostly in preclinical settings. GHK-Cu has legitimate research behind it for skin remodeling. Pickart and Margolina (2018, Cosmetics) reviewed evidence that copper-peptide complexes stimulate collagen and glycosaminoglycan synthesis in vitro and in animal models. That is not the same as injecting synthetic GHK-Cu subcutaneously and watching scars disappear in 50 days on a human. CJC-1295 is a growth hormone-releasing hormone analogue. Studies like Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed sustained GH elevation in healthy adults, but the subjects were not gym-goers chasing physique changes. No peer-reviewed trial has mapped CJC-1295 use to the kind of body composition changes implied here. The claim that co-injecting these two peptides reduces efficacy has no published pharmacokinetic basis that this writer could locate.
- GHK-Cu skin data: mostly in vitro or animal models, not 50-day subcutaneous human trials
- CJC-1295 GH elevation: documented in clinical settings, physique outcomes are not
- The "don't stack these two" rule: circulates in bodybuilding forums, not peer-reviewed literature
What did they get wrong (or right)?
He got the skeptical framing right. Saying he "never seen an actual transformation documented before" is a fair criticism of peptide content online, and attempting any kind of self-tracking is better than zero. Credit there. But the experiment has serious methodological problems. A single subject with no control condition, no blinded assessment, changing protocols mid-study, running out of a compound, and then doing something unspecified to "make up for missed days" is not an experiment. It is a personal diary. The claim that simultaneous GHK-Cu and CJC-1295 injection reduces efficacy is repeated confidently but sourced nowhere in the video. This matters because viewers may restructure their own protocols based on a claim with no traceable evidence. The unspecified thing he "wasn't supposed to do" is a genuine safety flag. Increasing doses or injection frequency of peptides that affect growth hormone secretion without clinical supervision carries real risk, including potential effects on insulin sensitivity and IGF-1 levels.
What should you actually know?
These peptides are not approved by the FDA for the uses described here. GHK-Cu appears in some topical cosmetic formulations where it has a longer safety record, but subcutaneous injection is a different route with different pharmacokinetics and no established dosing safety data in healthy humans outside clinical trials. CJC-1295 is not an approved drug. It is available as a research chemical and through some compounding pharmacies, but compounded peptides are not equivalent to pharmaceutical-grade products with validated manufacturing standards. Anyone seeing this video and thinking about replicating it should know that the creator changed his protocol three times, admitted errors, and withheld the actual outcome behind a YouTube link. That is not a clean data set. A physician specializing in endocrinology or sports medicine is the right starting point before anyone injects a growth hormone secretagogue, not a TikTok experiment with 50 days and shifting variables.
- GHK-Cu: some topical safety data exists, subcutaneous injection in healthy humans is not well-studied
- CJC-1295: affects the GH-IGF-1 axis, not something to self-administer without baseline labs
- Protocol changes mid-experiment invalidate before-after comparisons
- "Making up for missed days" by doing something unsanctioned suggests dose escalation, which is a risk
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Manuel Enrique's 50-day peptide test: what he got right, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Manuel Enrique's 50-day peptide test: what he got right should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
This video documents self-administration of at least two growth hormone-related and skin-remodeling peptides, GHK-Cu and CJC-1295, via subcutaneous injection over 50 days without reported physician supervision, baseline bloodwork, or consistent protocol adherence.
FormBlends verdict
This video documents self-administration of at least two growth hormone-related and skin-remodeling peptides, GHK-Cu and CJC-1295, via subcutaneous injection over 50 days without reported physician supervision, baseline bloodwork, or consistent protocol adherence. CJC-1295 is a growth hormone-releasing hormone analogue with documented effects on GH and IGF-1 levels that warrant monitoring, particularly in the context of undisclosed mid-experiment protocol deviations. The absence of final results in the TikTok itself means 410,000 viewers received a record of protocol errors and anecdotal skin observations with no outcome data to evaluate.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video documents self-administration of at least two growth hormone-related and skin-remodeling peptides, GHK-Cu and CJC-1295, via subcutaneous injection over 50 days without reported physician supervision, baseline bloodwork, or consistent protocol adherence. CJC-1295 is a growth hormone-releasing hormone analogue with documented effects on GH and IGF-1 levels that warrant monitoring, particularly in the context of undisclosed mid-experiment protocol deviations. The absence of final results in the TikTok itself means 410,000 viewers received a record of protocol errors and anecdotal skin observations with no outcome data to evaluate.
- GHK-Cu has in vitro and animal evidence for collagen stimulation (Pickart and Margolina, 2018, Cosmetics), but no peer-reviewed human trial supports subcutaneous injection for scar removal in 50 days.
- CJC-1295 demonstrably raises GH levels in humans (Teichman et al., 2006, JCEM), but elevated GH is not the same as documented physique improvement, and IGF-1 effects warrant lab monitoring.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GHK-Cu has in vitro and animal evidence for collagen stimulation (Pickart and Margolina, 2018, Cosmetics), but no peer-reviewed human trial supports subcutaneous injection for scar removal in 50 days.
- CJC-1295 demonstrably raises GH levels in humans (Teichman et al., 2006, JCEM), but elevated GH is not the same as documented physique improvement, and IGF-1 effects warrant lab monitoring.
- The creator changed his protocol at least three times, including running out of a compound and doing something unspecified he admitted was outside the plan, which invalidates any before-after comparison.
- The claim that stacking GHK-Cu and CJC-1295 reduces efficacy has no published pharmacokinetic support and appears to originate from online forums, not clinical research.
- Neither GHK-Cu (injectable) nor CJC-1295 is FDA-approved for the uses shown here. Compounded versions are not equivalent to pharmaceutical-grade drugs with validated purity and dosing.
- 410,000 viewers watched a highlight of protocol errors and were directed to a separate platform for outcomes, meaning most of this audience made judgments about peptide efficacy without seeing any actual results.
- Anyone considering growth hormone secretagogues like CJC-1295 should establish baseline GH, IGF-1, and fasting glucose labs with a physician before starting, not after watching a self-experiment with shifting variables.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Manuel Enrique · TikTok creator
410.7K views on this video
I Took Peptides for 50 Days to See if they’re a SCAM Full Video is out on YT: Manuel Enrique
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Manuel Enrique, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.